Results 61 to 70 of about 302,479 (284)

Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering [PDF]

open access: yesJAMA, 2018
Effects on specific fatal and nonfatal end points appear to vary for low-density lipoprotein cholesterol (LDL-C)-lowering drug trials.To evaluate whether baseline LDL-C level is associated with total and cardiovascular mortality risk reductions.Electronic databases (Cochrane, MEDLINE, EMBASE, TCTMD, ClinicalTrials.gov, major congress proceedings) were ...
Navarese E. P.   +9 more
openaire   +2 more sources

Changes in Immune‐Inflammation Status and Acute Ischemic Stroke Prognosis in Prospective Cohort

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Inflammation is a critical risk factor for poor outcomes in cerebral infarction. Prior studies focused primarily on baseline inflammation status, neglecting dynamic longitudinal changes. We try to investigate the association between immune‐inflammation status alterations and stroke prognosis, and evaluated three systemic biomarkers'
Songfang Chen   +11 more
wiley   +1 more source

Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain [PDF]

open access: yes, 2007
[Abstract] Although blood pressure (BP) control is crucial in hypertensive patients, clinical practice guidelines agree that the goal of treatment should be aimed at not only decreasing BP but reducing global cardiovascular risk.
Banegas JR   +11 more
core   +2 more sources

Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout

open access: yesArthritis Care &Research, EarlyView.
Objective Body mass index (BMI), glomerular filtration rate (GFR), and pretreatment urate levels have been reported to influence the urate‐lowering response to allopurinol. We investigated whether the fractional excretion of uric acid (FEUA) also modulates this response and relates to oxypurinol concentrations.
Pascal Richette   +13 more
wiley   +1 more source

Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk [PDF]

open access: yes, 2016
Therapeutic interventions that lower LDL-cholesterol effectively reduce the risk of coronary artery disease (CAD). However, statins, the most widely prescribed LDL-cholesterol lowering drugs, increase diabetes risk. We used genome-wide association study (
Asselbergs, Folkert W.   +7 more
core   +1 more source

Oral Dosed Organo‐Silica Nanoparticles Restore Glucose Homeostasis and β‐Cell Function in Diabetes Rats

open access: yesAdvanced Functional Materials, EarlyView.
An oral nanoplatform, MOP@T@D, which can maintain glucose homeostasis and restore islet β cells in diabetic rats is developed. It achieves efficient intestinal absorption and liver‐targeted delivery. The nanoparticle disintegrates only in response to hyperglycemia to release insulin on demand and provides antioxidant protection through selenoprotein ...
Chenxiao Chu   +14 more
wiley   +1 more source

A Human Kidney Tubuloid Model of Repeated Cisplatin‐Induced Cellular Senescence and Fibrosis for Drug Screening

open access: yesAdvanced Healthcare Materials, EarlyView.
Replicating aging and senescence‐related pathophysiological responses in kidney organoids remains a significant challenge. Human adult renal tubular organoid, tubuloids, are successfully developed recapitulating cellular senescence that is the central pathophysiological mechanism of chronic kidney disease (CKD).
Yuki Nakao   +20 more
wiley   +1 more source

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)‐Free Low‐Density Lipoprotein Cholesterol

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Background Accurate measurement of the cholesterol within lipoprotein(a) (Lp[a]‐C) and its contribution to low‐density lipoprotein cholesterol (LDL‐C) has important implications for risk assessment, diagnosis, and treatment of atherosclerotic ...
Weili Zheng   +13 more
doaj   +1 more source

A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels

open access: yesUpsala Journal of Medical Sciences
Background: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduces low-density lipoprotein cholesterol (LDL-C) levels and decreases the incidence of major ischaemic events in clinical trials.
Maria K. Svensson   +7 more
doaj   +1 more source

Oxidised LDL Cholesterol (Ox-LDL-C) and Ox-LDL-C/HDL Cholesterol (HDL-C) Ratio in Acute Coronary Syndrome Patients versus Chronic Coronary Artery Disease Patients on Statin Treatment [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2019
Introduction: Oxidised Low Density Lipoprotein Cholesterol (Ox-LDL-C) and High Density Lipoprotein Cholesterol (HDL-C) have antagonistic action in the development of atherosclerotic cardiovascular disease.
Sumina Cheriyan   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy